Singapore Seasonal Flu Vaccine Market Report 2022 to 2030

Singapore Seasonal Flu Vaccine Market Analysis

$ 3999

Singapore Seasonal Flu Vaccine Market is projected to grow from $xx Mn in 2022 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2022 - 2030. Seasonal Flu Vaccine market is growing globally due to the rising awareness of the necessity of getting the flu shot and the initiatives to expand immunization programmes, expanding government support and focus on seasonal flu vaccination, robust research and development activities with strong pipeline candidates, high influenza rates among children owing to demand for pediatric vaccines. GlaxoSmithKline, AstraZeneca, Seqirus, Pfizer, Novartis, Johnson & Johnson, Daiichi Sankyo Company, Bharat Biotech International Limited, Mitsubishi Tanabe Pharma Corporation are the key global market players in Seasonal flu vaccine market.

ID: IN10SGPH396 CATEGORY: Pharmaceuticals GEOGRAPHY: Singapore AUTHOR: Dr. Medha Sansanwal

Buy Now

Singapore Seasonal Flu Vaccine Market Analysis Summary

Singapore Seasonal Flu Vaccine Market is valued at around $7.7 Mn in 2022 and is projected to reach $14.2 Mn by 2030, exhibiting a CAGR of 7.95% during the forecast period 2023-2030.

A viral infection known as seasonal flu or influenza affects people every winter from December to March or April in the Northern Hemisphere and May to August or September in the Southern Hemisphere. The majority of seasonal influenza infections in humans are caused by the influenza virus types A and B, and an annual vaccination is advised due to the frequent virus changes. According to the WHO, there will be between three and five million instances of severe seasonal influenza infections and between 290,000 and 650,000 respiratory deaths from influenza, most of whom will be elderly people. Therefore, many nations advise yearly vaccination against seasonal flu, especially for high-risk populations like small children, expectant women, the elderly, and those with chronic illnesses. The strongest defense against the influenza virus is immunization and vaccines have been available for decades with a recent switch from trivalent to quadrivalent vaccines that protect against each two influenza type A and two B strains. GlaxoSmithKline, AstraZeneca, Seqirus, Pfizer, Novartis, Johnson & Johnson, Daiichi Sankyo Company, Bharat Biotech International Limited, and Mitsubishi Tanabe Pharma Corporation are the key global market players in the Seasonal flu vaccine market.

Market Dynamics

Market Growth Drivers

Rising awareness of the necessity of getting the flu shot and the initiatives to expand immunization programs, expanding government support and focus on seasonal flu vaccination, robust research and development activities with strong pipeline candidates.

Market Restraints

Vaccine supply challenges, vaccine hesitancy, and influenza strain mismatch between selected vaccine strains and circulating influenza strains lead to a decrease in the efficacy of vaccine and a longer timeline for vaccine production.

Competitive Landscape

Key Players

GlaxoSmithKline
AstraZeneca
Seqirus
Pfizer
Novartis
Johnson & Johnson
Daiichi Sankyo Company
Bharat Biotech International Limited
Mitsubishi Tanabe Pharma Corporation

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Market Segmentations For Singapore Seasonal Flu Vaccine Market

By type

Inactivated
Live attenuated

By Vaccine Type

Trivalent vaccines
Quadrivalent vaccines

By Age Group

Pediatric vaccines
Adult vaccines
Vaccines for senior citizens

By Distribution Channel

Hospitals
Clinics
Retail pharmacy
Online Pharmacy

By End User

Individuals
Healthcare providers
Government vaccination programs
Corporate vaccination programs

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.